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ABSTRACT 
Cognitive functioning and quality of life are salient factors in predicting mortality 
and morbidity in end-stage heart failure patients receiving cardiac assist devices while 
awaiting cardiac transplantation.  This study focused on cognitive functioning and self-
reported quality of life, neurological impairment, and depressive symptoms.  Of 103 
candidates for cardiac assist devices (HeartMate ThermoCardiosystems, Inc. [TCI] Left 
Ventricular Devices [LVAD] or Abiomed Biventricular Assist System [Abiomed]) as a 
bridge to cardiac transplantation at Hahnemann University Hospital, a total of 53 patients 
completed neuropsychological evaluations.  Cognitive factors included visual-spatial and 
verbal memories, motor speed, grip strength, and cognitive processing speed.  In 
addition, a total of 298 end-stage heart failure (ESHF) inpatients completed the same 
cognitive measures over the past decade.  Overall, cognitive functioning for both groups 
was within the normal range.  Not surprisingly, a series of t-tests revealed that ESHF 
inpatients performed better than MCAD candidates on most cognitive measures.  
However, MCAD cand idates performed better than ESHF inpatients on the Mental Status 
Exam, Visual Reproduction Immediate subtest of the Wechsler Memory Scale, and grip 
strength task with the nondominant hand.   
A total of 23 cardiac assist device candidates completed self-report measures of 
general and disease-specific quality of life, depressive symptoms, memory, and self-
reported neuropsychological symptoms.  Results did not support the hypothesis that 
depression would mediate the relationship between cognitive functioning and quality of 
life.  There were significant differences in quality of life between the three groups: ESHF, 
MCAD, and OHT warranting a discussion of the implications of various definitions of 
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quality of life.  There were no significant gender differences.  Major behavioral findings 
were 1) these patients are resilient in comparison to the general population; their 
cognitive functioning was not impaired and they were not depressed and 2) there was a 
strong relationship between self- report depressive symptoms and self-reported 
neurological impairment.   
 
 
Key Word List: CARDIAC ASSIST DEVICES, QUALITY OF LIFE, BEHAVIORAL & 
COGNITIVE FACTORS 
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CHAPTER 1 
INTRODUCTION 
 
 The current study investigates quality of life and cognitive functioning in patients 
with cardiac assist devices awaiting cardiac transplantation.  Quality of life is variously 
defined in the literature making it difficult to compare studies and draw conclusions.  
Furthermore, there is little research on quality of life and cardiac assist devices.  
Depression and cardiovascular disease are interrelated thereby interacting etiologically 
and phenomenologically.  Cardiac transplantation is associated with improvements in 
cognitive functioning.  However, the impact of cardiac assist devices on cognitive 
functioning is unknown.  As cardiac assist devices improve hemodynamics such as 
cardiac output and ejection fraction, they are expected to improve cognitive functioning 
and increase quality of life for end-stage heart failure patients.   
 The methodology of this study included administration of disease-specific and 
general quality of life questionnaires, depressive symptoms, memory, and self-reported 
neurological symptoms.  Questions were phrased to assess patients at three time periods: 
when first diagnosed with heart failure, with cardiac assist device, and following cardiac 
transplantation.  Additional cognitive evaluations included administration of 
neuropsychological measures assessing memory, motor speed, and cognitive processing 
speed both pre-device and post-transplant.   
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Background 
 Cardiovascular disease is the leading cause of mortality in the United States; 
nearly 500,000 people die annually (DeLunas & Potempa, 1999; Shapiro, 1996) and it 
accounts for one third of all global deaths (World Health Organization, 2000).  By 2010, 
cardiovascular disease is expected to be the leading cause of death worldwide (Word 
Health Organization, 2000).  Coronary Heart Disease (CHD) affects more than 11 million 
people in the United States.  Heart failure is a major public health problem in the United 
States.  It has a prevalence of 4 million, incidence of 400,000, and annual treatment costs 
of $10 billion (Moskowitz, Weinberg, Oz, & Williams, 1997).  Cardiovascular disease 
costs the United States over $117 billion per year and end stage heart failure is a major 
source of disability and loss or productivity (Shapiro, 1996).  According to the American 
Heart Association, the economic cost of cardiovascular disease was $298.2 billion in 
2000, including direct costs and indirect costs that include loss of productivity resulting 
from morbidity and mortality.    
Congestive Heart Failure 
 Congestive heart failure occurs when the heart is unable to pump enough blood to 
meet the body’s tissue’s needs.  When the heart fails, it is unable to pump out all of the 
blood that enters its chambers.  Ejection fraction refers to the percentage of blood 
pumped out during each heartbeat.  The New York Heart Association (NYHA) 
classification system of heart failure includes four classes, ranging from symptoms 
present with ordinary physical activity to symptoms present at rest.  With class IV, 
ejection fraction less than 20%, the patient experiences severe to complete limitation of 
activity, and symptoms occur with any physical exertion and even at rest.   
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Congestive heart failure affects 1% of adults (4,700,000 people according to the 
American Heart Association) in the United States, is diagnosed in 400,000 Americans 
annually, accounts for 250,000 deaths annually, and is the primary diagnosis for 900,000 
hospitalizations annually (Goldstein, Oz, & Rose, 1998).  In adults over the age of 35, 
one third of all deaths are due to coronary artery disease and the prevalence of congestive 
heart failure is increasing with the aging population (Shapiro, 1996).  Epidemiological 
studies indicate that over three million patients suffer from congestive heart failure: 30% 
with Class III or IV congestive heart failure (see Miller et al., 1995).  According to 
Thompson and Shaprio (1994), the major etiologies Class IV CHF are 50% idiopathic, 
40% ischemic, and 10% valvular or other miscellaneous.   
Treatment  
Treatment alternatives for congestive heart failure include coronary artery bypass 
surgery, dynamic cardiomyoplasty, partial left ventriculectomy (Dimento, 1998), 
implantation of cardiac assist devices, and cardiac transplantation.  Medication and 
invasive therapies such as coronary bypass grafting, cardiac assist device implantation, 
and cardiac transplantation relieve physical symptoms of heart disease.  Standard medical 
treatment for transplant candidates includes digoxin, diuretics, ACE inhibitors, 
vasocilators, beta blockers, and inotropic agents (Miller et al., 1995).  However, 
pharmacological treatment for New York Classification class IV end stage heart failure 
(ejection fraction < 20%) is only moderately successful.  Quality of life outcomes are 
much more complex and less well understood (DeLunas & Potempa, 1999).  While many 
factors influence quality of life, it is difficult to determine the precise impact of 
pharmacological or surgical interventions on quality of life.   
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Cardiac Transplantation.  Cardiac transplantation affords prolonged survival 
(Heshberger, 1997) and hopefully increased quality of life for patients dependent upon 
inotropes or cardiac assist devices.  Transplants became popular during the 1960’s 
although in the 1970’s they lost their popularity in the 1970’s due to high mortality rates 
(Nussbaum & Goldstein, 1992).  Orthotopic heart transplantation is now a routine clinical 
operation (Kugler, Tenderich, Stahlhut, et al., 1994).  There were 2,290 transplants in 
1997; 2,340 transplants in 1998 (National Institute of Health, 2000); and 2,184 in 1999 
(American Heart Association, 2000).  Survival rates for cardiac transplantation range 
form 70 to 80% at one year and five years (see Table 1 fo r a review of survival statistics).   
The demand for transplant hearts is much greater than the supply.  On an annual 
basis, between 20,000 and 40,000 Americans would benefit from cardiac transplantation 
(National Institute of Health, 2000); the number of donor hearts available annually is only 
2,000.  Many patients die while awaiting cardiac transplantation.  Patients on mechanical 
assist devices and patients in the intensive care unit requiring Inotropic medications share 
top priority for donor organs (Gil, 1989).  Transplant candidates receiving 
pharmacological treatment have a 10% inpatient survival rate and a 65% 5-year survival 
rate.  Complications of long-term immunosupression, allograft coronary artery disease, 
and the shortage of donor organs contribute to this success rate.  Despite many efforts and 
the development of new inotropes for medical management, the two-year survival rate is 
only 50% (Shapiro, 1996).   
Cardiac Assist Devices.  Mechanical Circulatory Support (MCS) is another 
therapy for severe end-stage heart disease," (Frazier, 2002, p. 178).  Due to the limited 
donor pool for cardiac transplantation, MCS offers an alternative and bridge to 
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transplantation (DeRose, Umana, Argenziano, et al., 1997; McCarthy et al., 1998; 
Morrone, Buck, Catanese, et al., 1996) and prevention of permanent organ damage 
during the waiting period for transplantation (Abou-Awdi & Frazier, 1992).  Mechanical 
circulatory support devices are indicated following acute myocardial infarction, during 
post cardiac-surgical cardiogenic shock, and as a bridge to cardiac transplantation 
(McGinley, Matthews, & Graham, 1990).  Cardiac assist devices can be classified as 
bridges to recovery, bridges to transplant, or alternatives to transplantation (Table 2).  
Many patients receive implantable LVADS for home use, resulting in continuation and 
improvement in their quality of life (Shapiro, 1992).   
In a recent comparison of LVAD and Inotropic treatment, Aaronson, Eppinger, 
Dyke, Wright, and Pagani (2002) found that the overall survival rate for the LVAD group 
(80 at one year and 77 at three and four years) was significantly better than for the 
Inotrope group (56 at one year and 44 at three and four years).  Furthermore, "the LVAD 
may end up being a permanent implant or destination therapy because the patient and 
physician have decided that the LVAD is safer than the morbidity an d mortality of 
immunosupression and transplantation," (McCarthy, 2002, p. 1256).  In the year 2010, 
70,000 patients annually are expected to be candidates for cardiac assist device (Petrucci, 
Kushon, Inkles, Fizpatrick, Twomey, & Samuels, 1999).  Psychiatric and 
neurobehavioral factors are important considerations in relation to the cardiac assist 
devices (Petrucci et al., 1999). 
Three types of cardiac assist devices: TCI, Abiomed, and Novacor were 
implanted at Hahnemann University Hospital in the past in the past decade with varying 
survival rates (53.3% for the TCI’s and 42.8% for the other devices).  The TCI LVAD 
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supports left ventricular function, thereby providing a bridge to transplant (Radovancevic, 
Frazier, & Duncan, 1992).  The Novacor Left Ventricular Assist System (LVAS) is an 
electronically driven device, which provides left ventricular support as bridge to 
transplant (Samuels, Kaufman, Morris, Brozena, Twomey, & Brockman, 1997).  The 
Abiomed Biventricular System (BVS) 5000 provides both left and right ventricular 
support; for patients following postcardiotomy shock (e.g., to wean patients from 
cardiopulmonary bypass or any irreversible cardiac situation such as viral myocarditis, 
myocardial infarction, intractable arrhythmia (Samuels, Kaufman, Thomas, Holmes, 
Brockman, & Wechsler, 1999; Samuels, Holmes, Thomas, Entwistle, Morris, Narula, & 
Wechsler, 2001).   
Hemodynamics 
 Hemodynamics are of important consideration in relation to neurologic and 
neuropsychological outcomes of cardiac assist device implantation and cardiac 
transplantation.  Hemodynamics include pulmonary arterial pressure (PAP), right atrial 
pressure (RAP), cardiac output (CO), right ventricle ejection fraction (EF), left atrial 
pressure (LAP), pulmonary vascular resistance (PVR), pulmonary vascular resistance 
index (PVRT), and cardiac index.  Prediction of RV failure is important for patient 
selection; preoperative PAP and low RV SWI were significant risk factors for RV failure 
and subsequent RVAD use (Fukamachi, McCarthy, Smedira, Vargo, Starling, & Young, 
1999).  Right atrial pressure, mediated by hydration, measures right ventricular function, 
whereas left ventricular ejection fraction and pulmonary artery wedge pressure measure 
overall systolic performance of the left ventricle (Bornstein, Starling, Myerowitz, & 
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Haas, 1995).  Hemodynamics are commonly used in assessing outcomes in studies of the 
impact of CT on cognitive functioning and quality of life variables.   
Quality of Life 
 Historically, the primary goal of surgery has been prolonging life with little 
emphasis on quality of life (Walter, Mohan, & Dahan-Mizrahl, 1992).  For example, with 
coronary bypass grafting is a readily accepted lifesaving procedure, with less emphasis 
on life enhancement (Radley, 1992).  Survival is only one goal of successful cardiac 
transplantation; obtaining quality of life (long-term psychological adaptation into the 
post-transplant years) is also critical (Dew et al., 1994).  Emphasis on quality of life with 
cardiac transplantation is increasing (McGee & Horgan, 1996).  Open-heart surgery 
greatly impacts the body’s physiology and subsequent quality of life.  (Walter et al., 
1992).  Transplant recipients typically worry about insufficient exercise, weight gain, 
overexertion, biopsy results, dying, negative mood, and negative body image (McGee & 
Horgan, 1996).   
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CHAPTER 2 
LITERATURE REVIEW 
 
Quality of Life 
 Consideration of quality of life rather than the simple consideration of length of 
life is becoming increasing salient and popular in medical care (Wenger, 1992).  Quality 
of life is of particularly essential consideration with respect to medical illnesses when 
considering therapeutic goals of alleviation of symptoms, improvement of functioning, 
limitations of the disease, and ameliorating possible psychological consequences.  Many 
life threatening illnesses cause decline in quality of life and some treatments may cause 
even further deterioration of quality of life (Wenger, 1992).   
Defining Health-Related Quality of Life (HRQL) 
HRQL is a multidimensional concept and difficult to define.  Albert (1998) argues 
that quality of life is not clearly definable due to cultural differences between patients.  
HRQL includes physical function, psychological state, social interaction, somatic state 
(Woodend, Nair, & Tang, 1998) and emotional and cognitive (Schumaker & Cazjkowski, 
1993).  Specific diseases impact quality of life.  For example, cardiovascular disease and 
treatments affect patients in different ways.  Assessment of quality of life is an important 
factor in determining treatment and health care (Woodend et al., 1998).  Treatments may 
even cause symptoms that adversely affect an individual’s quality of life (Shumaker & 
Cazjkowski, 1993).  However, in the case of end stage heart failure patients, tolerating 
the impact of cardiac assist devices, Inotropes, or transplantation is the only alternative to 
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prolong life.  “Critical assessments of their value [treatment options], as weighed against 
loss in life quality, are needed,” (Shumaker & Cazjkowski, 1993, p. 150).   
Stewart-Amidei (1995) defined quality of life as a multidimensional construct 
including coping, life satisfaction, emotional well being, material life, meaning in life, 
physical well-being, and social networks.  Furthermore, neurocognitive outcomes may 
affect quality of life and its assessment.  For example, neurologic, cognitive, and 
behavioral deficits make it more difficult to measure quality of life (Stewart-Amideri).  
Hume (1989) offers a simple definition of quality of life; “an individual’s perceived 
ability to function normally within society,” (p. 403).  Quality of life includes social 
functioning, cognitive functioning, emotional functioning, and overall health status 
(Hume, 1989).  Social functioning includes activities with family, friends, and in the 
workplace.  Cognitive functioning includes abstract reasoning, memory, judgment, and 
alertness.  Emotional functioning refers to mood changes and “sick role” behaviors.  
Economic status and patient’s perceptions about their general health status are other 
important components of quality of life (Hume, 1989). 
Intellectual functioning.  Walter, Mohan, and Dahan-Mizrahl (1992) found that 
patients experienced deficits in short-term memory, motor skills, and arithmetic due to 
cerebral hypoperfusion resulting from low cardiac output prior to cardiac transplantation.  
Immediately following transplantation, one fifth of patients suffered from delirium, 
orientation, and mania due to structural cerebral complication and side effects of 
medications such as steroids and other immunosuppressive agents.  However, cognitive 
impairment typically improved following recovery.   
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Emotional state.  Psychological reactions to cardiac transplantation include fear, 
anger, depression, and superstitious thinking (Walter, Mohan, & Dahan-Mizrahl, 1992), 
mood disturbance, disturbance of body image, increased marital and family stress, 
noncompliance, and organic brain syndromes (Shapiro, 1990).  Cardiac transplantation is 
most likely a last resort with an otherwise fatal alternative (Walter et al., 1992).  Delirium 
is particularly common immediately following the procedure with rates ranging from 4% 
to 18% (Shapiro).  Mood disturbance and mood lability are commonly related to the large 
doses of steroids immediately post-transplant (Shapiro, 1990).   
Occupational Functioning.  The goal of cardiac transplantation is long-term 
quality in mental and physical health, interpersonal relationships, physical and 
recreational activity, and employment.  Occupational functioning is of particular concern 
due to economic consequences.  Inability to return to work for heart transplant recipients 
and inadequate medical insurance coverage contribute to financial burden (Shapiro, 
1992).  “Given the high cost of the transplantation procedure, return to work is a highly-
desirable goal,” (Kavanagh, 1992, p. 413).   
Mai and McKenzie (1992) reported that 75% to 95% of patients return to normal 
pretransplant physical activity and 50% return to full time employment.  Reasons for 
failure to return to work include age, pre-transplant employment, type of work, and 
availability of disability payments (Kavanagh, 1992) and steroids.  In a survey of cardiac 
transplant patients, 69% who did not receive LVAD support were unable to return to 
work within one year of transplantation, whereas 92% of patients receiving LVAD 
support were able to return to work or capable of doing so (Abou-Awdi & Frazier, 1992).  
Kavanagh (1992) reported that 82% (under the age of 45), 76% (between 46 and 55), and 
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10% (over the age of 55 years) of patients who were working 6 months prior to transplant 
returned to work.  Cardiac rehabilitation also increased likelihood of returning to work.   
In a study of 25 heart transplant recipients at 7 transplant centers, 45% were 
employed, 36% unemployed, 13% medically disabled, and 6% retired (Paris, Woodbury, 
Thompson, Levick, Nothegger, Hukins-Slade, Arbuckles, & Cooper, 1992).  Of those 
employed, 87% returned to their previous employment following transplant and 13% 
found new employment.  Of those unemployed, 16% were working on job applications, 
whereas 63% had no current plans to seek employment.  Paris and colleagues (1992) 
concluded that length of disability prior to transplant, patients’ self-perception of being 
physically unable to work, and potential loss of health insurance or disability negatively 
influenced patients’ return to work.  On the contrary, patients whose health insurance 
policy did not accept their disability claims were more likely to seek and find 
employment (Paris et al., 1992).   
Social Functioning.  Social functioning refers to performing of social roles.  
Patient’s ability to relate to their family members and friends is an important aspect of 
recovery from cardiac transplant (Abou-Awdi & Frazier, 1992).  Cardiac transplantation 
often leads to role strain and adjustment (Shapiro, 1992).  Thus, patients and their family 
members often benefit from individual and family therapy to facilitate adjustment.  
“Patients who have a goal to live for, such as those wishing to return to work or spend 
more time at home have been shown to be better surgical candidates,” (Walter, Mohan, & 
Dahan-Mizrahl, 1992, p. 82).  “About 75-95% return to normal activities but only 50% 
return to previous employment, because of attitude problems . . . 80% returned to full or 
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part-time work compared with the 4.9% of patients working before the operation,” 
(Walter et al., 1992, p. 83). 
Coping ability greatly impacts psychosocial adjustment and quality of life 
following cardiac transplantation (Shapiro, 1992).  When a member of a couple 
undergoes cardiac transplantation, coping with heart transplantation involves two 
individuals (Grundbock, Bunzel, & Schubert, 1992).  During the waiting period for a 
donor heart, changes in family interaction and role assignment typically occur.  During 
the postoperative period, the couple restructures their lifestyle based on the transplant 
recipient’s unpredictable future. 
Body Image.  Body image disturbance typically occurs in 25% to 50% of heart 
transplant recipients (Shapiro, 1990) and is of particular concern for women and children 
(Shapiro, 1992).  Heart transplantation often changes patients’ perceptions of themselves 
and causes them distress about their physical appearance, particularly due to the side 
effects of steroids.   
Physical Functioning.  Physical functioning is another facet of quality of life 
referring specifically to a patient’s physical abilities and limitations and subsequent 
impact on quality of life.  Ades, Maloney, Savage, and Carhart (1999) reported that 
physical function in coronary patients correlated with age, gender, and mood state.  Older 
age, female gender, low exercise capacity and strength, and higher depression predicted 
poorer physical functioning.  In a study of functional health outcomes in sudden cardiac 
death survivors, Sauve (1995) found that few sudden cardiac death survivors experienced 
psychological distress, despite decreases in physical functioning and cognitive 
impairments.   
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Compliance.  Compliance with the prescribed medical regimen following cardiac 
transplantation is essential to continue life.  Furthermore, noncompliance is associated 
with poor quality of life and increased morbidity and mortality (Shapiro, 1992).   Poor 
compliance with the medical regimen ranges from 23% to 39% (Shapiro, 1990).  Young 
age, decreased family support, and geographical distance from the transplant center are 
associated with noncompliance.  Brennan, Davis, Buchhotz, and Kuhn (1987) found that 
personality disorders predicted poor quality of life following cardiac transplantation, 
specifically noncompliance with the medical regimen.   
Measuring Health-Related Quality of Life 
 The impact of an illness or intervention on a patient’s quality of life is a necessary 
and important aspect of medical research (Dempster & Donnelly, 2000) and evaluation of 
health care programs (Lalonde, Clarke, Joseph, Mackenzie, & Grover, 1999).  Quality of 
life assessment is widely accepted and further understood as a multidimensional concept 
including physical, psychological, and social functioning (de Boer, Spruijt, Sprangers, & 
de Haes, 1998).  However, the structure of quality of life is poorly understood.  de Boer 
and colleagues (1998) suggest that disease-specific quality of life can be considered one 
construct for different disease.   
 There are various views on quality of life assessment (e.g., Steven, 1998; Frank et 
al., 1998) although most researchers agree that the patient’s self-assessment is an 
important part of evaluation and treatment planning.  Quality of life measurement 
development requires validity, and reliability (Cohen, 1999).  Woodend, Nair, and Tang 
(1998) further recommend that quality of life measures are self-administered, relatively 
short (less than 60 minutes to administer), and simple to read and score.   
 Cardiac Assist Devices     21 
There is currently no gold standard for measuring quality of life (Hume, 1989). 
Dijkers (1999) distinguished between objective and subjective approaches to quality of 
life assessment.  Objective approaches emphasize common perception of quality of life, 
whereas subjective approaches emphasize individual cognition and life satisfaction and 
focus on affect.  In quality of life assessment, Guyatt (1994) recommends the following 
principles when using questionnaires: recognition of importance, training interviewers, 
and monitoring.  Of particular importance is recognizing the need for assessing health 
related quality of life for all members of transplant teams including surgeons, 
cardiologists, nurses, psychologists, neuropsychologists, and clinical social workers.  
Subsequently, training and monitoring of quality of assessment must include follow-up 
evaluation. 
Health-Related Quality of Life Measures  
Health-related quality of life measures are either generic (pertaining broadly to 
quality of life) or disease-specific (pertaining to specific aspects of a disease).  Dempster 
and Donnelly (2000) found that the Medical Outcomes Study Short Form-36 (SF-36) was 
strongest psychometrically general measure of health-related quality of life when 
compared to other measures such as the Nottingham Health Profile and the Sickness 
Impact Profile.  Brown and colleagues (2000) also found the SF-36 to be a more sensitive 
measure of health related quality of life than the Nottingham Health Profile in a study of 
survivors of myocardial infarction.  In terms of disease-specific measures of quality of 
life, Dempster and Donnelly (2000) support use of the Quality of Life after Myocardial 
Infarction questionnaire for heart failure classes I – III.  The Kansas City 
Cardiomyopathy Questionnaire (KCCQ) is a valid and reliable measure of disease-
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specific quality of life for patients with congestive heart failure (Green, Porter, 
Bresnahan, & Spertus, 2000).  The KCCQ is more sensitive than the Minnesota Living 
with Heart Failure Questionnaire and the SF-36 (Green et al., 2000).    
Quality of Life Research 
In a recent study of quality of life and cognitive status, Dew and colleagues 
(2001) found that patients with ventricular assist devices had poorer cognitive status and 
were less likely to return to work than non VAD patients.  However, this study did not 
include a complete neuropsychological evaluation and therefore did not determine precise 
levels of cognitive impairment.  Dew and colleagues (2001) also purported that cognitive 
impairment leads to reductions in daily functioning and quality of life.   
Riedinger, Dracup, and Brecht (2000) conducted a study of predictors of quality 
of life in women with heart failure.  They found that for women (mean age = 61, mean 
ejection fraction = 27%), higher levels of dyspnea, life stresses, and New York Heart 
Association class predicted lower levels of quality of life.  In addition, smoking and 
vasodilator medication use were associated with decreased quality of life.  Ischemic heart 
failure was associated with decreased social life dissatisfaction and increasing age was 
associated with increased general life satisfaction. 
 In a study of patients with coronary heart disease surviving coronary arrest, 
Motzer and Stewart (1996) found that social status, perceived social support, self-esteem, 
and instability of chronic illness trajectory accounted for 50% of the variance in quality 
of life.  In addition, they found that sense of coherence added 15% to the incremental 
variance in quality of life. They suggested that sense of coherence is a salient factor 
predicting quality of life in cardiac patients.  Motzer and Stewart (1996) defined a sense 
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of coherence in terms of comprehensibility, manageability, and meaningfulness of life 
with respect to change.  A sense of coherence is typically crystallized by the age of 30, 
but amenable to change with intervention.  In another study, Delunas and Potempa (1999) 
found that hostility, anxiety, and threat appraisal affect quality of life and outcome 
following treatment for CHD.   
 Bunzel, Grundbock, and Wollenek (1992) found that patients exhibited 
improvement the following dimensions of quality of life: physical, emotional, mental, 
vocational, sexual status, financial situation, leisure activities, partnership, and overall 
quality of life.  However, patients did not exhibit improvement in financial and status 
following transplantation.  Etiology such as coronary artery disease or cardiomyopathy 
and age did not account for any variance in quality of life or life satisfaction.  Konstam, 
Surman, Hijjazi, and colleagues (1997) studied 29 patients undergoing cardiac 
transplantation, assessing quality of life at 5 intervals.  They found that patients exhibited 
significant improvements in quality of life physical scores on the Sickness Impact Profile 
at four months post-transplant, compared with 5 months pre-transplant.   
 In a study of patients with dilated cardiomyopathy, Steptoe, Mohabir, Mahon, and 
McKenna (2000) found that patients had significant impairments in physical functioning, 
role limitations due to physical and emotional problems, social functioning, mental 
health, perceptions of general health, sleep, and vitality.  Quality of life impairments 
correlated with low shortening fraction, high left ventricular end diastolic diameter, heart 
failure, and mitral regurgitation.  Patients also had higher levels of anxiety and depression 
compared with a normal sample.  Psychological adjustment was associated with quality 
of life and psychological well-being.   
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Quality of Life for Patients Awaiting Cardiac Transplantation.  Patients in end-
stage heart failure who undergo cardiac transplant evaluation often have one year or less 
to live, while their physical and psychological conditions progressively decline 
(Nussbaum & Goldstein, 1992).  Health status if the most salient predictor of quality of 
life: a multidimensional construct with objective and subjective dimensions (Shapiro, 
1992; Evans, 1992).  Objective indicators include ability to work, employment, 
functional ability, and health status, whereas subjective indicators include psychosocial 
and psychological variables such as well-being, life satisfaction, psychological affect, and 
happiness.   
“The success of heart transplant has meant considerable pressure to demonstrate 
that the enormous costs are justified in benefits for quality of life as well as expectation 
of life,” (Mayou, 1990, p. 105).  Research indicates that patients and families “require 
extra psychological and social support if they are to avoid distressing psychosocial 
complications and gain maximum benefit,” (Mayou, 1990, p. 105).  Multiple assessments 
at multiple times of quality of life in cardiac transplant recipients provide insight into 
changes in quality of life and allow for meaningful comparisons (Caine, Sharples, & 
Wallwork, 1992).  For example, in patients undergoing cardiac transplantation, better 
psychological functioning is associated with better sleep patterns, better social 
functioning, improved vitality, less loneliness, and older age (Littlefield, Abbey, Fiducia, 
Cardella, Greig, Levy, Maurer, & Winton , 1996).  Transplantation is associated with 
overall improved quality of life despite impairments in physical and social functioning 
due to difficulty in complying with the medical regimen and the intrusive nature of the 
course.   
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 Factors contributing to higher stress levels among patients awaiting cardiac 
transplantation include requiring a heart transplant, having a terminal heart disease, and 
worrying family members (Porter, Krout, Parks, et al., 1994).  Porter and colleagues 
reported the most common and effective coping strategies: thinking positively, using 
humor, and trying to keep life as normal as possible.  They further suggest that cardiac 
transplant teams should encourage positive coping strategies in patients and families 
awaiting transplantation and monitor patients and their family members.  Konstam, 
Surman, Hijjazi, and colleagues (1999) investigated the impact of stress levels of patients 
and their spouses on quality of life (using the Sickness Impact Profile) both pre- and post-
cardiac transplantation.  They found that patients’ stress levels and spousal stress levels 
predicted quality of life functioning, accounting for 58% of the variance in the patient at 
one month pre-transplantation.  Patients commonly respond to stress and cardiac illness 
with psychosocial dependency, the need for emotional protection and social support after 
a significant health status change, which impedes psychological adjustment (Riegel, 
Glaser, Thomas, Gocka, & Gillespie, 1997).   
Quality of Life and Cardiac Assist Devices.  There is insufficient research on 
quality of life and cardiac assist devices (Moskowitz, Weinberg, Oz, & Williams, 1997; 
Baldwin, Radovanncevic, Duncan, et al., 1991).  In terms of quality of life and cardiac 
disease, problems with quality of life research include “overemphasis on general 
concepts, neglect of mental state, failure to recognize the range of individual response, 
neglect of individual meaning of quality of life, and neglect of consequences for the 
family,” (Mayou, 1990, p. 100).  Problems with quality of life measurement include 
“unrepresentative samples, reliance on ad hoc measures, excessive preoccupation with 
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standard general measures, neglect of mental state, neglect of other aspects of quality of 
life of particular importance to patients and families, measures often insensitive to 
clinically important change, self-report preferred to interview-based measures, and failure 
to compare with control groups,” (Mayou, 1990, p. 100).   
Dew, Kormos, Winowich, and colleagues (1999) found that quality of life for 
LVAS outpatients was better than LVAS inpatients and OHT outpatients on physical, 
emotional, and social functioning domains.  QOL for LVAS outpatients also improved 
over their own QOL before discharger, particularly in the physical functioning and 
emotional status domains.  In another study of 27 cardiac assist device recipients, 67% 
experienced major complications including bleeding, serious infection, renal failure, and 
stroke (Kanter, Rizevich, Pennington, et al., 1988).  Of the 23 survivors 74% returned to 
Class I heart status, 9% Class II, 13% Class III, and 4% Class IV.  In terms of quality of 
life and employment, eight returned to full time employment, three were retired, four 
attended school, three attended preschool, one was a homemaker, and one was 
unemployed but free of symptoms.  Overall, patients had satisfactory long-term quality of 
life and survival.   
Moskowitz, Weinberg, Oz, and Williams (1997) investigated quality of life for 
long-term LVAD use as compared to the alternative of medical therapy including quality 
of life assessments at pre-LAVD implantation, peri-LVAD, and post-transplant.  
However, their Quality of Life measure consisted of a health ranking (0=dead, 1=full 
health) and patients’ responses to a standard gamble (e.g., “Imagine you are no longer a 
candidate for cardiac transplantation.  You are also told that a new treatment for your 
heart disease is available (a pill),” (Moskowitz et al., 1997, p. 1769).  Patients are 
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required to make a choice between their current treatment and the possibility of the 
panacea pill.  Limitations of their study include the utility of their quality of life measure 
and incomplete data collection, which is common for studies of seriously ill patients.  
Dew, Kormos, Winowich, and colleagues (2000) reported that quality of life during VAD 
support is equal to or better than quality of life for other transplant candidates without 
VAD support.  Shapiro, Levin, and Oz (1996) suggested that neuropsychiatric factors 
play a great role in quality of life and outcome for LVADs and cardiac transplantation.   
 In a most recent study of quality of life and LVAD implantation, Grady, Meyer, 
Mattea, et al. (2001) found patients were satisfied with their lives, experienced low 
amounts of stress and functional disability, coped well, and perceived themselves as 
having good health and quality of life.  Two weeks following device implantation, 
patients reported significantly better quality of life, less symptom distress, greater 
satisfaction with health and functioning.  However, patients reported self-care disability 
and socioeconomic dissatisfaction following device implantation.   
 With LVAD support, patients may return to NYHA Class I cardiac status and 
experience improved functional status such that they may become self-caring and leave 
the hospital, thereby reducing healthcare costs and improving their morale (Frazier, 1994; 
Myers, Dasse, Macris, et al., 1994).  Dew and colleagues (2000) reported that outpatients 
with ventricular assist device support were more concerned about device noise and risk of 
stroke than inpatients, while inpatients were more concerned about infection.   
 In a retrospective study of 12 VAD survivors, 16% reported that the emotional 
effects of the device were worse than the physical effects, whereas 50% were unsure 
(Cleavinger & Smith, 1993).  In addition, 83% endorsed that they would recommend a 
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device to someone who needed it, and 67% would reconsent to using the device again if 
needed.  In conclusion, Cleavinger and Smith (1993) identified the following quality of 
life issues for the device patient: optimization of patient care, dealing with complications, 
limitations in mobility, and possible termination of support, and obtaining adequate rest 
(device noise, physical discomfort, anxiety, and interruptions to check device 
performance).   
Quality of Life in Primary Caregivers.  In addition to investigation quality of life 
with in heart failure patients, it is also important to investigate the quality of life of the 
primary caregivers.  Stressful factors for primary caretakers of transplant recipients 
include increase in tasks not completed, having a family member seriously ill, and 
financial strain (Savage & Canody, 1999).  The spouse of a transplant candidate plays a 
key role in determining patient well-being and quality of life, although sometimes at the 
expense of the psychological and physical well-being of the spouse (Konstam, Surman, 
Hijjazi, et al., 1997).  For example, spousal support is the best predictor of medical 
compliance for treatment of hypertension. End-stage heart failure affects the quality of 
life of both the patient and the spouse in interacting, complex, dynamic ways.  Specific 
measures of quality of life in cardiac spouses do exist (e.g., Quality of Life for Cardiac 
Spouses; Ebbesen, Guyattm, McCartney, & Oldridge, 1990).  In a study of QOL and 
LVAS patients, family caregivers reported increased caregiving burden following patient 
discharger, but overall well-being was not adversely affected (Dew, Kormos, Winowich, 
et al., 1999).  
 Dew, Switzer, DiMartini and colleagues (2000) investigated human factors for 
ventricular assist device recipients and their family caregivers via interview.  They found 
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that patients’ and caregivers’ perceptions of health status and well-being did not differ.  
Patients’ concerns included infection, difficulty sleeping due to the location of the 
driveline exit site, device malfunction, and device noise.  All patients reported concerns 
about physical functional limitations, psychological distress, and reduced quality of life.   
Quality of Life After Heart Transplantation.  Difficulties for patients following 
cardiac transplantation include employment, financial burden (e.g., issues around welfare, 
health insurance, and inability to return to work), and satisfaction with sexual 
relationships (see Shapiro, 1992 for a review).  Most transplant recipients report 
improved mood and well-being following transplantation.  However, steroids may induce 
psychiatric problems both directly by their effect on the central nervous system) and 
indirectly by their side effects such as weight gain.   
Psychological adjustment for children following transplantation is particularly 
difficult around issues of body image and effects on their families (Shapiro, 1992).  
Psychological adjustment is a major contributing factor to quality of life; poor 
psychological adjustment leads to decreased quality of life and increased physical 
morbidity (Dew, Kormos, Winowich, et al., 2001).  Cognitive functioning is another 
important factor contributing to quality of life following cardiac transplantation (Schall, 
Petrucci, Brozena, Cavarocchi, & Jessup, 1989).   
Recommendations 
Various clinicians and researchers provide recommendations for protocols to 
measure quality of life and cognitive functioning in these patients.  For example, Avis, 
Czaiowski, Dew, and colleagues (1995) recommended a protocol to measure HRQL for 
device patients with the following QOL dimensions: cognitive, emotional, social, 
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physical, sexual/intimacy, productivity, overall well-being, device specific, open ended 
questions, and TrailMaking, Logical Memory, Digit Symbol, and the Rey Complex 
Figure at Baseline, 12 months, and 24 months.   
Behavioral Factors 
Physiologically and metaphorically, the heart is an essential part of our identity 
and social function (Shapiro, 1996).  Psychiatric disorders such as Type A behavior 
pattern and hostility, anxiety, and depression frequently coexist with cardiovascular 
disease.  Depression is of particular concern for cardiac patients due to the high 
prevalence and depression and the physiological correlates of depression and 
cardiovascular disease.  The following is a review of psychiatric considerations before 
and after cardiac transplantation (CT) and predictors of successful CT.   
Depression and Cardiovascular Disease 
The comorbidity of depression and cardiovascular disease is “an inevitable 
consequence of the relationship between the two conditions,” (Roose, 2001, p. 19).  
Depression and cardiovascular disease interrelate etiologically and phenomenologcially.  
Specifically, depressed patients have increased platelet activity, thereby increasing risk 
for platelet- induced ischemic events.  Depressed patients also have heart rate variability 
from decreased parasympathetic tone.  Cardiovascular patients with depression are at 
increased risk for fatal ischemic heart disease and depressed patients have a high rate of 
sudden cardiovascular death.  Depression affects 20% of myocardial infarction (MI) 
patients (18% meet criteria for Major Depressive Disorder and 27% experience 
depressive symptoms) and is associated with reduced quality of life and occupational 
functioning and increased mortality (Shapiro, 1992).  Depression in patients with 
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coronary artery disease predicts increases in rehospitalization, disability, healthcare cost 
and decreases in symptom relief following surgery and survival. (Brummett, Babyak, 
Barefoot, et al., 1998).  In addition, depressive symptoms may impact cognitive 
functioning; in a study of 40 adults, Williams, Little, Scates, and Blockman (1987) found 
that depressed adults reported more memory problems than nondepressed adults, perhaps 
due to depressive cognitive distortions such as negative self-evaluation.   
Psychiatric Considerations Before Cardiac Transplantation 
“Heart transplantation confronts the patient with major physical, psychological, 
and social demands, both before and after the operation.  Psychological adjustment with 
these stressors requires effective coping abilities,” (Zumbrunnen, 1989, p. 66).  The heart 
transplantation process requires multidisciplinary team evaluations (Sears, Rodrigue, 
Sirious, Urizar, & Perri, 1999) providing initial medical and psychiatric histories and 
making numerous and complex decisions (Houser, Konstam, & Konstam, 1992).  In 
addition to severe limitations in quality of life and prognosis, the absence of physical of 
emotional factors, which would hinder survival, determine recommendation for 
transplantation.  Candidates for cardiac transplantation are in end stage heart- failure 
(Class IV) with ejection fraction less than 20%, are in rapid decline, and may have 
symptoms of fatigue, insomnia, anorexia, hepatic and pulmonary congestion, and poor 
exercise tolerance (Levenson & Olbrisch, 1993).  For these patients, their prognosis is 
quite poor without successful transplantation.   
Psychiatric contraindications of cardiac transplantation include florid psychosis, 
alcohol or drug dependence, personality disorder, and poor social support (Zumbrunnen, 
1989).  Exclusion criteria for cardiac transplantation include serious medical illnesses 
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(e.g., advanced pulmonary disease or me tastatic cancer).  Most transplant programs 
(70%) exclude patients for active schizophrenia, dementia, suicidal ideation, suicide 
attempts, mental retardation, current alcohol or substance abuse (Levensen & Olbrisch, 
1993).  However, exclusion for tobacco use, obesity, noncompliance, criminality, 
personality disorder, mild mental retardation, controlled schizophrenia or affective 
disorders, and a history of alcohol or substance abuse lead to controversy for transplant 
programs.  Social support is another important factor for determining candidate selection 
and predicting success (Table 3).  Due to the ceiling effect of social support in the cardiac 
transplant population, as it is required for transplant candidacy, social support was not 
investigated in the current study.   
 Psychiatric problems with transplant recipients include bipolar mood disorder due 
to steroids, major depression, delirium, pain, sexual dysfunction, family adjustment 
problems, and noncompliance (Shapiro, 1996).  Fifty percent of heart transplant 
candidates have psychiatric disorders such as adjustment disorder and psychological 
factors such as depression and anxiety affecting their medical condition (Levensen & 
Olbrisch, 1993).  Other psychiatric issues include denial of illness, noncompliance, 
ambivalence, substance abuse, and cognitive impairment.  Common cognitive deficits 
include neuropsychological deficits resulting from heart disease, MIs, and cardiac 
surgery, delirium resulting from cyclosporine toxicity, steroid psychosis, or rejection 
encephalopathy, hypoxia, electrolyte disturbance, renal or hepatic failure, hyperglycemia, 
acute infection, drug toxicity, and cerebrovascular emboli.   
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Psychiatric Factors Following Transplantation 
Transplant recipients have a high prevalence of adjustment disorders, organic 
mental syndromes, and other psychiatric problems (Shapiro, 1992).  Prevalence rates of 
major depression and steroid- induced depression range from 10% to 20% and often go 
undiagnosed and untreated.  Difficulties for heart transplant recipients following 
transplantation include inability to return to work, psychopathology, sleep disturbance, 
organic brain syndrome, mood-cognitive-perceptual disorder, marital distress, anxiety, 
depression, and psychosocial adjustment to illness (see Shapiro & Kornfeld, 1989 for a 
review).  Affective disorders are particularly common in patients taking high doses of 
prednisone following transplantation.   
Shapiro and Kornfeld (1989) evaluated the prevalence of psychiatric disorders 
and psychosocial problems following cardiac transplantation.  Fifty-one percent of 
patients had affective disorders (chiefly steroid-related) including mood lability and 
irritability, grandiosity (22%), major depressive episodes (11%), and anxiety symptoms 
(26%).  Patients also experienced cognitive, social, and occupational difficulties (Shapiro 
& Kornfeld, 1989).  Magni and Borgherini (1992) reported that of 47 transplant 
recipients; generalized anxiety disorder (35%) and major depression (19%) were the most 
frequent psychiatric diagnoses prior to cardiac transplantation.  Two patients developed 
post-transplant delirium.  Psychological distress (i.e., depression, anxiety, psychoticism, 
and interpersonal sensitivity) improved following transplantation.   
Family difficulties following transplantation include spousal anxiety, depression, 
and anger, acting out by children, family conflict, impotence, fear of sexual intercourse, 
guilt, and disappointment (Shapiro & Kornfeld, 1989).  Sears, Rodruge, Green, and Mills 
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(1995) studied 83 transplant recipients (mean age = 55.9) and found that trait anxiety was 
a significant predictor of increased symptom frequency and problems and decreased 
mental health.   
In a study of long-term follow-up of cardiac transplantation, Jones, Taylor, 
Downs, and Spratt (1992) found that patients’ depressive and anxiety symptoms 
decreased following transplantation while quality of life scores (based on the Nottingham 
Health Profile) increased.  Bullinger, Angerman, and Kemkes (1992) reported long-term 
improvements in mood (less depression and anxiety) and quality of life (based on the 22-
item Psychological General Well-being Index) for transplant recipients.  Kugler, 
Tenderich, Stahlhut, and colleagues (1994) found that patients awaiting transplantation 
displayed high ratings of anxiety and depression.  Following surgery, patients 
experienced significantly fewer anxious and depressive symptoms.   
Mai, McKenzie, and Kostuk (1990) investigated psychological adjustment and 
quality of life in 27 heart transplant recipients (24 survivors) and found that prior to 
transplantation, 14 had psychiatric diagnoses.  Four months following transplantation, 12 
had psychiatric diagnoses.  Pre-operative psychiatric diagnoses correlated with poor 
medical compliance following transplantation.  Physical activity, employment, 
psychological adjustment, and sexual activity improved significantly following 
transplantation.  Thus, they concluded that heart transplantation leads to substantial 
improvement in quality of life and psychosocia l adjustment 12 months following surgery.  
However, there is little research examining long-term quality of life and psychosocial 
adjustment. 
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Functional Limitations.  Functional limitations following heart transplantation 
include impairments in daily care activities (e.g., eating, self-care, and use of 
transportation), ability to lift objects, aggressive exercise, tiredness, loss of appetite, 
coughing, and swelling due to fluid retention, depression, altered mental status, and social 
restrictions (Houser, Konstam, & Konstam, 1992).  Vocational limitations include regret 
over loss of work roles, income, social contacts, and self-perception (Houser et al., 1992).   
Psychological Limitations.  Psychological limitations include anxiety, depression, 
ambivalence, anger, and emotional lability (Houser, Konstam, & Konstam, 1992).  
Ambivalence is associated with difficulties in facing the seriousness of cardiac illness, 
fear of transplant, quality of life concerns, anxiety, and depressive symptoms (Kuhn, 
Myers, & Davis, 1988).  The transactional and developmental framework for 
understanding adaptation to chronic illness includes the acute phase (ambiguity and 
uncertainty), the chronic phase (establishment of medical regimen), and the 
terminal/bereavement phase (recognition that the condition is beyond recovery) (Reiss & 
Kaplan De-Nour, 1989 cited in Houser et al., 1992).    
 In a longitudinal study of heart transplant patients, Dew, Roth, Schulberg, and 
colleagues (1996) found that pre-transplant psychiatric history, poor social support, use 
of avoidant coping strategies for coping with medical illness, and low-self-esteem 
predicted increased risk for psychiatric disorder (anxiety and depression) following 
cardiac transplantation.  In a follow-up study of 191 transplant recipients evaluated up to 
three years post-transplant, Dew, Kormos, Winowich, and colleagues (2001) found that 
pre-transplant psychiatric history, female gender, longer hospitalization, impaired 
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physical functioning, and fewer social supports were cumulative risk factors for increased 
risk of psychiatric disorder post-transplant.   
Compliance.  In a study of 125 transplant recipients. Shapiro, Williams, Foray, 
Gelman, Wukich, & Sciacca (1995) found that substance abuse history, personality 
disorder, living arrangements, and global psychosocial risk were associated with 
compliance problems.  In addition, global psychosocial risk was associated with rejection 
episodes and education inversely correlated with transplant coronary artery disease.  Mai, 
McKenzie, and Kostuk (1990) found that psychiatric diagnoses correlated with poor 
medical compliance in 27 transplant recipients.  Transplantation was associated with 
improvements in quality of life; physical activity, employment, and psychological 
adjustment improved six months following transplantation.  In a study of post-transplant 
compliance with diagnostic tests (coronary angiograms, treadmill test, 24 hour Holter 
monitoring, radionuclide ventriculography, and 24 hour creatinine clearance) Grady and 
colleagues (1993) found that compliance ranged from 63% to 97% one year post-
transplant.  There was a trend for reduced compliance for diagnostic testing five years 
post-transplant; less than 80%.  Demographic variables were not significantly related to 
compliance.   
Predictors of Successful Cardiac Transplantation 
 In a study of 50 patients receiving cardiac transplantation, Bunzel and Wollneck 
(1994) investigated psychosocial predictors of successful surgery.  Empathy, care and 
support by one partner, few demands for emotional communication, self-control, ability 
to cope with stress, emotional stability, high frustration tolerance, low aggression levels, 
and younger age predict successful cardiac transplantation.  Social support from a partner 
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was the most salient predictor of success.  Conversely, education, occupation, social 
status, indication for transplantation, length of stay in ICU, pre-operative anxiety and 
depression, and scores on Spitzer’s quality of life index did not significantly predict 
clinical success.   
 Dew, Simmons, Roth, and colleagues (1994) examined psychosocial predictors of 
vulnerability to distress in the first year post-transplant for 72 transplant recipients.  They 
found that patient’s anxiety and depression levels were significantly elevated in the early 
post-transplant period but improved over time.  However, anger-hostility symptoms were 
not elevated.  Transplant recipients with a history of psychiatric disorder, younger age, 
lower social support, exposure to recent negative life events, poor self-esteem, poor sense 
of mastery, and use of avoidant coping strategies had higher levels of distress and poorer 
outcomes. 
 Historically, quality of life following cardiac transplantation improved due to the 
use of cyclosporine: a potent immunosuppressive agent (Cabrol, Gandjbackhch, Pavie, et 
al., 1992).  Rejection is the main health risk for mortality following transplantation.  
Cyclosporine suppresses the “usual clinical, electrical, and hemodynamic symptoms of 
rejection,” (Cabrol et al., 1992, p. 389).  However, cyclosporine is not without side 
effects and complications such as chronic nephrotoxicity and elevated serum creatinine 
levels.  The second major health risk factor for transplant recipients is occlusive coronary 
lesions or accelerated graft arteriosclerosis, which occurs in 25% of patients 5 years 
following transplantation.  The three stages of accelerated graft arteriosclerosis include 
early inflammatory arteritis (between 3 and 8 months following transplant), late 
obliterative fibrous arteritis (2 years post-transplant), and late atherosclerosis (2 years 
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post-transplant). 
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Cognitive Functioning 
 The brain consists of 2% of total body weight, receives 15% of the cardiac output 
and 20% of the body’s total oxygen consumption (Roman, Kubo, Ormaza, et al., 1997).  
Evaluation of patients before and after cardiac transplantation is a good model for 
evaluating decline in cognitive functioning due to heart failure.  In addition, evaluation of 
patients receiving cardiac assist devices will help us to understand the effects of heart 
failure and left ventricular dysfunction.   
Risk Factors for Decline in Cognitive Functioning  
 Cardiac surgery with cardiopulmonary bypass is associated with increased risk for 
complications in CNS functioning such as coma, seizures, hemiparesis, abnormal 
reflexes, and changes in memory functioning (Harter, Williams, George, & Mutchnick, 
1990).  Specifically, identification of disorientation during the early postoperative course 
(2-5 days post-surgery) is a critical predictor of verbal and spatial memory outcomes.  In 
another study of self- reported cognitive functioning following cardiac surgery, Kareken, 
Williams, Muchnick, and colleagues (1992) found that risk factors (e.g., age and number 
of arteries bypassed) did not correlate with cognitive dysfunction.  However, 
psychological distress was associated with memory loss and cognitive impairment.  
Vingerhoets, deSoete, and Jannes (1995) also found that higher levels of depression and 
state anxiety were associated with decline in cognitive functioning following 
cardiopulmonary bypass.   
“Mesial temporal structures (including the hippocampus) may be particularly 
vulnerable to the adverse effects of hypoperfusion, because theses structures fall within 
the watershed areas where the vascularization is less robust and collateral circulation may 
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not be adequate,” (Roman, Kubo, Ormaza, et al., 1997, p. 696).  Recovery of memory 
deficits following transplantation implies that memory deficits are due to 
hypometabolism, which is reversib le, in contrast to anoxic or vascular lesions, which 
cause permanent structural damage.  Forty-two percent of patients undergoing cardiac 
bypass surgery show decline in mental ability five years later due to brain damage related 
to the surgery (Grady, 2001).  However, decline in cognitive functioning may also be 
related to increasing age.   
Neurologic Complications 
 Neurologic complications following cardiac surgery include becoming comatose 
and never regaining neurologic functioning again, stroke (0.8% to 5.2% incidence), 
delirium and confusion (10% incidence), and more commonly: disorientation, slowness 
awakening from anesthesia, and agitation requiring restraint (Borowicz, Goldsborough, 
Selnes, & McKhann, 1996).  It is important to monitor cognitive status following cardiac 
surgery, particularly cardiac transplantation.   
Neuropsychological Outcomes 
 Neuropsychological testing includes orientation and attention, perception, 
memory, verbal functions and language skills, construction, concept formation and 
reasoning, executive functions and motor performance  (Lezak, 1995).  Thus, evaluating 
patients before cardiac surgery and following cardiac surgery is imperative (Borowicz, 
Goldsborough, Selnes, et al., 1996).  Many studies evaluated cognitive functioning 
following cardiac surgery in using different populations, different neuropsychological 
evaluation, different timelines of evaluation, and different definitions of cognitive change 
(see Borowicz et al., 1996 for a review).   
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Neuropsychological impairment is frequently associated with cardiac disease, 
open-heart surgery, and coronary artery bypass surgery (Bornstein, Starling, & 
Myerowitz, 1992).  The high prevalence of neuropsychological impairment suggests 
diffuse cerebral dysfunction.  They reported consistent correlations between 
neuropsychological impairment and cardiovascular function.  Specifically, higher right 
atrium pressure correlates with neuropsychological impairments on Verbal IQ scores 
from the WAIS, Verbal Concept Attainment test, Visual Reproduction from the Wechsler 
Memory Scale, Trail Making A & B, Pegboard, and Tactual Performance Test.  
Conversely, better neuropsychological performance was associated with higher 
stroke/volume index and cardiac index.   
 Psychological investigations of heart transplant recipients include research on 
candidate selection and preoperative status, research on the psychological and 
neuropsychological sequelae of transplantation, and prospective research on the 
predictive nature of psychosocial and quality of life variables (see Strauss et al., 1992 for 
a review).  They investigated psychosocial, neuropsychological and neurological status in 
71 survivors of 100 heart transplants.  Forty of the 71 completed extensive examination 
including EEG, auditory and visually evoked potentials, neuropsychological testing (i.e., 
the WAIS and Trail Making tests), and questionnaires concerning anxiety, depression, 
ways of coping, personality characteristics, and life satisfaction.  They found that 
psychosocial and neuropsychological preoperative status did not significantly predict 
early postoperative complications.  However, 25% of the patients had significantly higher 
levels of affective and neuropsychological impairment compared to the normal 
population.   
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 Riether, Smith, Lewison, and colleagues (1992) found that 51 heart and 61 liver 
transplant recipients demonstrated significant improvements in neurocognitive 
functioning, depressive symptoms, and quality of life following transplantation.  They 
suggested that structural or biochemical changes may explain neurocognitive 
improvements on the following measures: Mental Status Exam, California Verbal 
Learning Test, Wisconsin Card Sorting Test, and Trail Making Test.  In a study of 
cognitive functioning and cardiopulmonary bypass surgery, Vingerhoets, Jannes, 
DeSoete, and VanNooten (1996) found that patients’ performance on the Auditory Verbal 
Learning Test declined significantly immediately following surgery.  However, six 
months later patients displayed significant improvement in long-term memory.   
Cardiac Transplantation and Cognitive Functioning 
Cardiac transplantation places patients at risk for central nervous system 
complication including difficulties related to the surgery itself, maintenance of the donor 
heart, function of the transplanted heart, and homograft rejection (Nussbaum & 
Goldstein, 1992).  Cognitive side effects of cardiac transplantation include deficits in 
attention-concentration, organizational skills, verbal learning, abstract reasoning, 
psychomotor speed, concept formation, and cognitive flexibility and memory deficits.  
An ejection fraction of less than 20% correlates with difficulty organizing and learning 
new information.  Clearly, cognitive functioning of transplant recipients is an important 
factor and predictor of medical compliance.  Inability to follow the post-transplant 
medical regimen can lead to serious complications.  Clinically, it is important to tailor 
treatment strategies based upon a patient’s cognitive strengths and weaknesses.   
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Bornstein, Starling, Myerowitz, and Haas (1995) found preliminary evidence that 
cardiac transplantation may improve cognitive functioning.  Patients with end stage heart 
failure experience impairments in memory, motor speed, and higher-level information 
processing.  These cognitive deficits may be explained by low cardiac output, a prior 
neurologic event, emotional deficits, medications, or malaise associated with severe 
illness.  Cardiovascular measures include right atrial pressure, left ventricular ejection 
fraction, pulmonary artery wedge pressure, cardiac index and stroke/volume index.  
Following transplantation, patients experienced significant cognitive improvements, 
however with limited clinical significance.  Furthermore, neuropsychological deficits 
may be partially reversible by cardiac transplantation.  In another study of cognitive 
functioning, Jones, Taylor, Downs, and Spratt (1992) reported significant improvement 
short-term memory, psychomotor speed, and mental arithmetic.  These improvements 
may be explained by increased blood and oxygen supply to the brain as well as improved 
quality of life.  Improvements in cognitive status predicted increased likelihood of 
patients returning to work.   
In another study of transplant patients, Roman, Kubo, Ormaza and colleagues 
(1997) found that cardiac transplantation improved memory.  Pre-transplant candidates 
had normal intelligence levels, attentional, language, and executive functioning despite 
impaired memory functioning although their memory improved significantly to normal 
levels following transplantation.   Nussbaum and Goldstein (1992) reported that 
significant improvements in cognitive functioning do not occur following transplantation, 
whereas motor speed does improve significantly.   
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 Schall, Petrucci, Brozena, Cavarocchi, and Jessup (1989) assert that cognitive 
functioning is a key determinant of quality of life in transplant recipients.  Cognitive 
functioning determines the ability to manage the demands of daily living, follow a 
complex medical regimen, and adapt to the challenges imposed when resuming social 
and occupational roles, thus determining quality of life.  However, they did not find 
significant improvement in cognitive functioning following cardiac transplantation on 
neuropsychological measures (54 completed pre-transplant evaluation and 20 completed 
follow-up evaluation), despite overall improvement in physical health.   
Self-Report Assessment of Cognitive Functioning 
Historically, self-report assessment has been an important part of 
neuropsychological assessment (O’Donnell, DeSoto, & DeSoto, 1993).  Despite the 
unreliability of self-report measures accurately assessing actual behavior, memory self-
assessment has much greater accuracy (Zelinski, Gilewski, & Thompson, 1980).  For 
example, if you ask a patient: “How is your memory?” they will most likely tell the truth, 
whereas they might be inclined to give a socially desirable response to a more 
provocative question: “Have you ever felt down in the dumps due to your heart failure?”  
Metamemory, awareness of memory ability, is a significant factor impacting overall 
memory.  Self- reported neurological symptoms ascertain only a patients’ subjective self-
perception of neurological impairment.  Thus, collateral objective measures of 
neurological impairment are also necessary. 
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SUMMARY 
 
 The current study investigated quality of life and cognitive functioning in patients 
with cardiac assist devices awaiting cardiac transplantation.  A review of the relevant 
literature on quality of life as well as cognitive and behavioral factors for these patients 
was provided.  Quality of life is difficult to define and variously defined in the literature 
making it difficult to compare studies.  Most research indicates that cardiac 
transplantation leads to improvements in quality of life across a variety of domains.  
However, there is little substantial research on quality of life and cardiac assist devices.  
Behavioral factors (e.g., psychiatric diagnoses) are important issues when considering 
transplant evaluation and have va rying prevalence rates.  Depression is the most salient in 
cardiac populations due to the high prevalence of Major Depressive Disorder and 
depressive symptoms and the interrelationship of cardiovascular disease and depression.  
In terms of cognitive factors, cardiac transplantation is associated with improvements in 
cognitive functioning (e.g., memory).  However, the impact of cardiac assist devices on 
cognitive functioning is unknown.  As cardiac assist devices improve hemodynamics 
(e.g., cardiac output and ejection fraction), they are expected to improve cognitive 
functioning and increase quality of life for end-stage heart failure patients.  Thus, the 
current study will investigate the following hypotheses.   
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Hypotheses 
Hypothesis 1 
Mental Status (Mental Status Exam number of errors): ESHF inpatients will have 
fewer errors than MCAD candidates.   
Hypothesis 2 
Verbal Memory (Rey Auditory-Verbal Learning Test): ESHF inpatients 
remember more words than MCAD candidates.   
Hypothesis 3 
Visual Memory: ESHF inpatients will perform better than MCAD candidates on 
the Benton VRT and the Hooper VOT.   
Hypothesis 4 
Memory (Wechsler Memory Scale Memory Quotient): ESHF inpatients will have 
a greater memory quotient than MCAD candidates.   
Hypothesis 5 
Logical Memory (Wechsler Memory Scale Logical Memory Immediate & 
Delay): ESHF inpatients will perform better on Logical Memory than MCAD candidates.   
Hypothesis 6 
Visual Reproduction (Wechsler Memory Scale Visual Reproduction Immediate 
and Delay): ESHF inpatients will perform better on Visual Reproduction than MCAD 
candidates.   
Hypothesis 7 
Cognitive Processing Speed (Trail Making A & B): ESHF inpatients will take less 
time for Trail Making A & B than MCAD candidates.   
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Hypothesis 8 
Motor Functioning: ESHF inpatients will tap more times for a 10 second trial and 
demonstrate greater grip strength with both hands than MCAD candidates.   
Hypothesis 9 
Depression will mediate the relationship between cognitive functioning and 
quality of life.   
Hypothesis 10 
Quality of life will improve after cardiac transplantation compared with quality of 
life with device.   
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CHAPTER 3 
METHOD & PROCEDURES 
 
 The purpose of this study was to assess cognitive and psychosocial outcomes with 
cardiac assist devices.  Specifically, this study evaluated quality of life, depressive 
symptoms, and cognitive functioning in patients receiving cardiac assist devices while 
awaiting cardiac transplantation. 
Subjects 
 Participants were 53 cardiac assist device candidates and 298 end-stage heart 
failure inpatients.   
 Participant Inclusion Criteria.  All potential (or previous) cardiac assist device 
recipients referred by Cardio-Throacic surgery at Hahnemann University Hospital, 
cardiac transplant recipients, and end-stage heart failure patients were included.  Specific 
inclusion criteria included those that could read English at the 8th grade level, able to sit 
up in bed, not on a ventilator (saturation ratio > 90%), and those not on a nasal canula.   
 Participant Exclusion Criteria.  Exclusion criteria included severe comorbid 
neurologic or psychiatric disorders, inability to read English at the 8th grade level, 
inability to sit up in bed, those on a ventilator (saturation ratio < 90%), those on a nasal 
canula, and those who chose not to participate.   
Procedure 
 Patients completed pre-device and post-transplant cognitive and psychosocial 
evaluations as part of their hospital course.  Upon admission to Inpatient Heart 
Failure/Transplant Unit or upon appointment in the Outpatient Cardiology Clinic, 
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participants completed the self- report questionnaires either in the waiting room or 
bedside.  In addition, the psychosocial protocol was sent out via USMail to all device 
recipients from the last decade so they could complete questionnaires at home and return 
them to the clinic.   
Psychosocial Evaluation.  Psychosocial evaluation included administration two 
quality of life measures (Kansas City Cardiomyopathy Questionnaire and the Medical 
Outcomes Study Short Form-36), a depression inventory (BDI-II), the Memory 
Questionna ire (MQ), and the Neuropsychological Impairment Scale (NIS).  Because 
questionnaires were administered at one point in time, subjects were at different time 
periods in their treatment.  Questions were phrased to assess the patient’s responses to 
each item “before your heart failure,” “with your cardiac assist device”, and “following 
cardiac transplant.”   
Cognitive Evaluation.  Cognitive evaluation included administration of the 
following neuropsychological measures: Wechsler Memory Scale, Bender Gestalt Test, 
Reitan-Indiana Aphasia Screening Test, Rey Auditory-Verbal Learning Test, Trails A & 
B, Benton Visual Retention Test, Finger Tapping, and Grip Strength. 
Retrospective Assessment.  Retrospective assessment of prior cardiac assist 
device and transplant recipients included mailing of the psychosocial questionnaires.  
Participants who chose to participate in this part of the study signed the consent form, 
completed the questionnaires, and returned a copy of the consent form and the 
questionnaires via USMail.  The purpose of this retrospective assessment was to provide 
meaningful comparisons and norms for this end stage heart failure population receiving 
cardiac assist devices and transplantation.   
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Measures 
Quality of Life 
Kansas City Cardiomyopathy Questionnaire (KCCQ).  The KCCQ is a reliable 
and valid 23- item self- report measure of quality of life for patients with congestive heart 
failure (Green, Porter, Bresnahan, & Spertus, 2000; Spertus et al., 2002).1  The KCCQ 
assesses physical limitations, symptoms, self-efficacy, social interference, and quality of 
life.  The KCCQ has adequate reliability and convergent validity: r=0.46 to 0.74, p 
<.0001 with congestive heart failure patients (ejection fraction <40).   
Medical Outcomes Study Short-Form 36 Health Survey (SF-36).  The SF-36 
assesses eight components of health status including 1) physical functioning, 2) role 
limitations, 3) bodily pain, 4) social functioning, 5) general mental health (psychological 
distress and psychological well-being), 6) role limitations, 7) vitality (energy/fatigue), 
and 8) general health perceptions (Ware & Sherbourne, 1992).  The scale also includes a 
mental component summary and a physical component summary.  The SF-36 has 
acceptable reliability and validity (Ware & Sherborune, 1992) and has recently been used 
with cardiac populations (Brown, Melville, Gray, Young, Skene, & Hampton, 2000).     
Depression 
Beck Depression Inventory II (BDI-II).  The BDI-II is the most prominently and 
frequently cited self- report measure of depression (Beck, 1967; Beck, Steer, & Brown, 
1996; Beck, Ward, Mendelson, Mock, & Erbaugh, 1961).  The 21- item questionnaire 
assesses four major components of depression: behavioral, affective, cognitive, and 
physiological.  Numerical values assigned to each statement range from 0 to 3 indicate 
increasing severity.  For example, Item 1 includes the following statements: I do not feel 
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sad (0), I feel sad (1), I am sad all the time and I can’t snap out of it (2), and I am so sad 
or unhappy that I can’t stand it (3).  Total BDI-II scores, indicating severity of 
depression, range from 0 to 63.  According to Beck’s clinical criterion, a score less than 4 
indicates minimal depression, between 5 and 13 mild depression, between 14 and 20 
moderate depression, and above 21 severe depression.  The BDI-II is a valid measure of 
depression for both psychiatric and normal samples with good internal consistency (alpha 
= .81) and stability coefficients in the .70 range.  The BDI consistently and significantly 
correlates (ranging from .60 to .90) with clinical ratings of depression (Shaver & 
Brennan, 1991; see Sears, Rodrigue, Sirios, Urizar, & Perri, 1999 for norms for cardiac 
patients).   
Cognitive Functioning 
The Neuropsychological Impairment Scale (NIS).  O’Donnell, DeSoto, DeSoto, 
and Reynolds (1994) developed the NIS, a self-report measure of neuropsychological 
symptoms.  Historically, self-report assessment has been an important part of 
neuropsychological assessment.  For example, Halstead developed a Head Injury 
Questionnaire and memory has been commonly assessed by self-report.  The NIS 
contains 95 items assessing neuropsychological symptoms (80 items), affective 
disturbance (10 items), and test-taking attitudes (5 items).  Items are rated on a 5-point 
Likert scale ranging from not at all (0) to 4 extremely (4).  NIS scores consist of three 
summary scores: the Global Measure of Impairment Index (sum of 80 items), Total Items 
Checked (number of neuropsychological items with scores greater than zero), and 
Symptom Intensity Measure (ration of GMI/TIC).  The NIS also includes an observer 
report form, which allows primary caregivers to describe how they perceive the patient.   
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NIS scores correlate with other neuropsychological tests of cognitive impairment 
and has adequate and reliability and validity (O'Donnell, DeSoto, & DeSoto, 1993).  
Research indicates that patients rate their academic skills and speech/language 
functioning more accurately than their memory, attention, and higher level problem 
solving abilities.   
Neuropsychological Evaluation 
 The neuropsychological evaluation was consistent with the protocol given to heart 
transplant patients for the past 18 years to follow suit and afford comparisons between 
new data and old data from similar patients.  For example, the original Wechsler Memory 
Scale was used as opposed to the Wechsler Memory Scale-III.   
Verbal Memory 
Rey Auditory-Verbal Learning Test (Rey AVLT).  The Rey AVLT assesses 
immediate memory span, practice effects, as well as retroactive and proactive 
interference (Rey, 1964).  Patients are instructed to recall a list of 15 words including 5 
presentations of the words, a distracter trial, and delayed memory recall of the original 
list of 15 words.  The examiner records the order in which the patients recall the words to 
measure their pattern of recall.   
Benton Visual Retention Test (BVRT).  The BVRT assesses visual-perceptual 
ability, constructional skills, and immediate visual memory (Benton, 1974).  Patients are 
instructed to reproduce abstract geometric designs from memory.  Scoring includes 
counting total number of designs drawn correctly and the total number of errors.  Types 
of errors include omissions and additions, distortions, preservations, rotations, 
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misplacements, and size errors.  Youngjohn, Larrabee, and Crook (1993) provide adult 
age- and education-correction norms for the BVRT.   
Memory 
Wechsler Memory Scale (WMS).  The WMS includes assessment of personal and 
current information, mental control, logical memory, digit span, visual reproduction, 
associate learning, and delayed logical memory, visual reproduction, and associate 
learning (Wechsler, 1987).  Poor performance on the WMS corresponds with memory 
disorders and left hemisphere lesions in particular (Lezak, 1995).   
Visual Memory 
Hooper Visual Organiza tion Test (HVOT).  The Hooper VOT was originally 
developed to identify patients with organic brain conditions (Hooper, 1983; Lezak, 1995).  
Patients are presented with thirty pictures of “cut up” objects and asked to identify them.  
Scores range from 0 to 30 (one point for each correct identification of the picture).  
Scores under 20 indicate organic brain pathology.   
Language 
 The Reitan-Indiana Aphasia Examination assesses language disorders and left 
hemisphere dysfunction.  Tasks include ability to name objects, read, write, copy objects, 
and recognize numbers and letters.  Greater than 6 errors indicate brain injury.   
Cognitive Processing Speed 
 The Halstead Reitan Battery includes two measures of attention and cognitive 
processing speed: Trail Making A and B (Halstead, 1947).   
Trail Making A.  Trail Making A consists of 25 (numbered from 1 to 25) circles 
on a sheet of paper.  The patient is instructed to “connect the dots” in ascending 
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numerical order.  The amount of time for completion and the number of errors are 
recorded.  Performance in less than 39 seconds indicates impairment.   
Trail Making B.  Trail Making B consists of 25 (numbered from 1 to 13 and 
lettered from A to L) circles.  The patient is instructed to “connect the dots” alternating 
numbers and letters (e.g., 1A, 2B, 3C, etc.).  Trail Making B tests recognition of numbers 
and letters, ability to find the correct number or letter, and time pressure.  Completion in 
less than 91 seconds indicates impairment.   
Motor Functioning 
 The Haltead Reitan Battery includes two measures of motor functioning: finger 
tapping and grip strength (Halstead, 1947).   
Finger Tapping.  The Finger Tapping test measures fine motor control, kinesthetic 
ability, motor speed, and visual-motor coordination.  Patients were instructed to tap their 
forefinger of both their dominant and nondominant hands (separately) on a key on a small 
clipboard.  Patients typically perform better with the dominant hand.  Completion of less 
than 61 taps with the dominant hand indicates impairment, whereas less than 46 taps with 
the nondominant hand indicates impairment.  However, better performance with the 
dominant hand by 15-20% or more indicates impairment of the nondominant hand.  
Grip Strength.  Patients were instructed to grip the handle of a device measuring 
grip strength first with their dominant and then with their nondominant hand.  Strength of 
less than 40 kg with the dominant hand indicates impairment, whereas less than 35 kg 
with the nondomaint hand indicates impairment.   
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Data Analysis 
 The first 8 major hypotheses regarding cognitive functioning required a series of 
t-tests to compare the ESHF inpatients and MCAD candidates.  ESHF inpatients were 
expected to perform better than the MCAD candidates on the Mental Status Exam (make 
fewer errors), Rey Auditory-Verbal Learning Test, Benton Visual Retention Test, Hooper 
Visual Organization Test, Wechsler Memory Scale (have higher Memory Quotients), 
Logical Memory Immediate and Delay (remember more word phrases), Visual 
Reproduction Immediate and Delay, Trail Making A & B (have quicker cognitive 
processing speed), and motor functioning (perform better on finger tapping and grip 
strength).   
 Depression was hypothesized to mediate the relationship between self- reported 
neurological impairment and quality of life.  A series of regression analyses followed by 
a partial correlation tests for mediation (Baron & Kenny, 1986).  Finally, the hypothesis 
that quality of life will improve following cardiac transplantation compared with quality 
of life with device required a one-way analysis of variance.   
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CHAPTER 4 
RESULTS 
 
Demographic Information 
 Neuropsychological data was collected on 53 (28 male/25 female) cardiac assist 
device candidates (MCAD).  The age range for this group was between 21 and 69 (mean 
= 51.9).  Etiology included 23 ischemic, 25 idiopathic, and 5 other.  Neuropsychological 
data was also obtained for 298 (245 male/53 female) end-stage heart failure (ESHF) 
patients.  For the ESHF group, age ranged between 17 and 68 years (mean = 49.42).  
Etiology included 153 ischemic, 100 idiopathic, 10 structural, 25 congenital, 1 viral, and 
1 other.  There were no significant differences in age, gender, or etiology of heart failure 
between the two groups (Table 5).   
Neurological Events 
 Of the 53 MCAD candidates (8 TCI, 8 Abiomed, 8 Novacor, and 14 onto OHT), 
several experienced pre-surgical neurological events such as a loss of consciousness 
following a motor vehicle accident, circulation problems, left-sided weakness, multiple 
Transient Ischemic Attacks and symptoms, and a right cerebrovascular event.  In order to 
meet criteria for a neurological event, neurological symptoms had to warrant medical 
attention.  Of the 53 MCAD candidates, 14 experienced post-surgical neurological events 
including cerebrovascular events, brainstem cerebrovascular events, delirium, 
hemiplegia, and Transient Ischemic Attacks.   
 Of the 602 end-stage heart failure patient, 53.3% (339) had no pre-neurological 
events, 18.1% (109) had 1 pre-event, 3.5% (21) had 2 pre-events, .2%(1) had 3 pre-
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events, .2% (1) had 4 pre-events, and .2% (1) had 8 pre-events.  Of the 602 ESHF 
patients, 53.7% (323) had no post-neurological events, 12.6% (76) had 1 post-event, .3% 
(2) had 2 post-events, .2% (1) had 3 post-events, .2%(1) had 4 post-events, and 1.3% (8) 
had 9 post-events.   
Comparing ESHF and MCAD Candidates 
 Cognitive functioning overall was better for end-stage heart failure patients 
(ESHF) than for cardiac assist device candidates (MCAD) across most cognitive 
domains, with the exception of the Mental Status Exam, Visual Reproduction subtest of 
the Wechsler Memory Scale, and grip strength task.  A series of t-tests with Bonferonni 
adjusted alpha levels compared the two groups on all cognitive measures and the two 
groups were significantly different across all cognitive domains (p < .001; see Table 6). 
Hypothesis 1: MSE.  A t-test indicated that the ESHF group (1.99 errors) had a 
greater number of errors than the MCAD group (.75 errors) on the Mental Status Exam: t 
(11, 243) = 3.45, p < .005.   
Hypothesis 2: Verbal Memory.  ESHF inpatients remembered more words than 
MCAD candidates on the Rey Auditory-Verbal Learning Test.  A t-test indicated that the 
ESHF group remembered significantly more words than the MCAD group on all tria ls.  
The ESHF group remembered an average of 41.27 words, whereas the MCAD group 
remembered an average of 37.49 words: t (34, 131) = 20.34, p < .001.  The results for 
individual trials are presented in Table 7.   
Hypothesis 3: Visual Memory.  On the Benton Visual Retention Test, the ESHF 
group performed better than the MCAD candidates.  The ESHF group (6.27 correct) drew 
more items correctly than the MCAD group (4.92 correct): t (12, 147) = 7.75, p < .001.  
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In addition, the MCAD group had more errors (7.08 errors) than the ESHF group (5.81 
errors): t (12, 148) = 6.12, p < .001.   
 On the Hooper Visual Organization test, the ESHF group (24.82) obtained more 
items correct than the MCAD group (22.92): t (12, 181) = 30.19, p < .001.   
Hypothesis 4: Memory.  On the Wechsler Memory Scale, the ESHF inpatients 
(103.54) had a great memory quotient than the MCAD candidates (97.85): t (12, 160) = 
25.33, p < .001.   
Hypothesis 5: Logical Memory.  On the Logical Memory subtest of the WMS, the 
ESHF group (7.25) performed better than the MCAD group (6.29): t (25, 167) = 15.60, p 
< .001.  The ESHF group (5.16) also performed better than the MCAD group (4.63): t 
(22, 162) = 7.89, p < .001.   
Hypothesis 6: Visual Reproduction.  On the Visual Reproduction (Immediate) 
subtest of the WMS, the MCAD group performed better than the ESHF group (8.07): t 
(24, 165) = 10.02, p < .001.  The ESHF group (6.30) performed better than the MCAD 
group (5.72) on the Visual Reproduction (Delayed) subtest: t (22, 160) = 6.11, p < .001.   
Hypothesis 7: Cognitive Processing Speed.  The ESHF group (48.19 seconds) 
took less time to complete Trails A than the MCAD group (68.23 seconds): t (12, 168) = 
6.18, p < .001.  In addition, the ESHF group (102.57 seconds) took less time to complete 
Trails B than the MCAD group (119.25 seconds): t (11, 167) = 9.84, p < .001.   
Hypothesis 8: Motor Functioning.  Results on the grip strength task were contrary 
to the original hypothesis.  On the grip strength task with the dominant hand, the ESHF 
group (33.00 kg) was stronger than the MCAD group (31.25 kg): t (12, 110) = 14.50, p < 
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.001.  On the grip strength task with the non-dominant hand, the MCAD group (31.57 kg) 
was stronger than the ESHF group (30.69 kg): t (12, 109) = 17.27, p < .001.   
 On the finger tapping task with the dominant hand, the ESHF group (44.93) 
performed better than the MCAD group (41.18): t (14, 127) = 15.86, p < .001.  With the 
non-dominant hand, the ESHF group (40.26) performed better than the MCAD group 
(38.52) on finger tapping: t (14, 127) = 18.04, p < .001.   
Quality of Life Data 
Thirty-three questionnaires were mailed out to cardiac assist device recipients 
living at home post-transplant.  After two sets of reminders (including a reminder letter 
from their attending physician), a total of 17 questionnaires were ultimately obtained 
(51.52% return rate).  Several questionnaires were completed in the hospital by inpatients 
as well.  The total number of completed quality of life questionnaires was 23 cardiac 
assist device candidates with time period in parentheses. 
Quality of Life 
 KCCQ Scores.  Overall, the KCCQ had high internal consistency from this 
sample with an internal alpha of .96.  First, KCCQ sum scores were computed by 
summing all items on the KCCQ as a composite measure of quality of life.  Sum scores 
ranged from 30 to 116 with a mean of 78.57, (SD = 27.84).  Spertus, Tooley, Jones, and 
colleagues (2002) divided baseline KCCQ sum scores into four ranges: 0-24, 25-49, 50-
74, 75-100. 
Two subscale scores for the KCCQ were computed: Activity Limitation and 
Symptom Presence.  Activity Limitation scores included patients’ rankings of 1 
(extremely limited), 2 (quite a bit limited), 3 (moderately limited), 4 (slightly limited), 5 
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(not at all limited), and 6 (limited for other reasons or did not do the activity) of the 
following activities: dressing yourself; showering/bathing; walking 1 block on level 
ground; doing yardwork, housework or carrying groceries; climbing a flight of stairs 
without stopping; hurrying or jogging (as if to catch a bus); hobbies, recreational 
activities; working or doing household chores; visiting family or friends outside of your 
home; and intimate relationships with loved ones.  KCCQ Activity scores, based on 10 
items, ranged from 10 to 53 with a mean of 33.13 (SD – 15.62).  Thus, higher scores 
indicate greater activity limitation, whereas lower scores indicate less activity limitation.   
 Symptom presence scores for the KCCQ required patients’ rankings of 1 
(extremely bothersome), 2 (quite a bit bothersome), 3 (moderately bothersome), 4 
(slightly bothersome), 5 (not at all bothersome), and 6 (no symptom present) of the 
following symptoms: shortness of breath; fatigue, or ankle swelling; swelling in your 
feet, ankles, or legs; swelling in your feet, ankles, or legs when you woke up in the 
morning; fatigue bothering you; fatigue limiting your activities; shortness of breath 
bothering you; shortness of breath limiting your activities; shortness of breath causing 
you to sleep upright in a chair; felt discouraged or down in the dumps because of your 
heart failure?; how much has your heart failure limited your enjoyment of life?  Thus, 
higher scores indicate greater symptom distress, whereas lower scores indicate less 
symptoms distress.  KCCQ symptom scores, based on 10 items, ranged from 10 to 60 
with a mean of 34.95 (SD = 13.93).   
 SF-36 Scores.  The SF-36 had reasonable internal consistency for this sample 
with an alpha value of .57.  First, SF-36 sum scores were computed by summing all items 
on the SF-36, providing a composite quality of life score.  Two subscale sum scores were 
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computed for the SF-36 including Sf-36 Activity and SF-36 Pain/Distress.  SF-36 
Activity scores required patients to rank 1 (limited a lot), 2 (limited a little), and 3 (not 
limited at all) the following 10 activities: vigorous activities; moderate activities; lifting 
or carrying groceries; climbing several flights of stairs; climbing one flight of stairs; 
bending, kneeling, or stooping; walking more than a mile; walking several blocks; 
walking one block; and bathing or dressing yourself.  Higher scores indicate greater 
ability to engage in activities, whereas lower scores indicate greater activity limitation.   
 SF-36 Pain/Distress scores required patients to rank 1 (not at all), 2 (slightly), 3 
(moderately), 4 (severe), and 5 (very severe) the following 12 questions: How much 
bodily pain have you had?; How much did pain interfere with your normal work 
(including both work outside the home and housework)?; Did you feel full of pep?; Have 
you been a very nervous person?; Have you felt so down in the dumps that nothing could 
cheer you up?; Have you felt calm and peaceful”; Did you have a lot of energy?; Have 
you felt downhearted and blue”; Did you feel worn out?; Have you been a happy person?; 
and Did you feel tired?  Higher scores indicate greater pain/distress, whereas lower scores 
indicate less pain/distress.   
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Depressive Symptoms  
 BDI II Scores.  BDI II total scores ranged from 0 to 37 (Mean = 11.78, SD = 
9.00).  Depressive symptoms (total BDI score) correlated positively with 
neuropsychological impairment (NIS total): r = .78, p < .01 and negatively with quality of 
life (KCCQ sum): r = -.65, p < .05.   
Self-Reported Neurological Impairment 
 NIS Scores.  NIS total scores ranged from 15 to 60 (Mean = 57.35, SD = 33.03).  
Higher scores indicate greater self-reported neuropsychological symptoms.  For the 
purposes of quality of life analyses, cognitive functioning was operationalized by self-
reported neuropsychological impairment 
Correlations 
 Correlations between depressive symptoms, neuropsychological impairment, and 
quality of life are shown in Table 8.  There was a significant positive correlation between 
BDI total scores and NIS total scores: r = .79, p < .01 and significant negative correlation 
between BDI total scores and quality of life (KCCQSUM): r = -.65, p < .05.  In addition, 
there was a significant negative correlation between BDI total scores and KCCQ 
Pain/Distress: r = -.69, p < .01 and a significant positive correlation between BDI total 
scores and SF-36 Pain: r = .50, p < .05.  NIS total scores have an inverse relationship 
with KCCQ Pain/Distress: r = -.54, p < .01.   
Hypothesis 9 
Depression was hypothesized to mediate relationship between cognitive 
functioning and quality of life.  A series of univariate regression analyses followed by a 
partial correlation (Baron & Kenny, 1986) tested this mediational hypothesis.  First, 
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cognitive functioning (NIS total scores) was correlated with depression: r = .79, p < .01 
and quality of life (KCCQSUM): r = -.50, NS.  Then, cognitive functioning was 
correlated with quality of life while controlling for depressive symptoms: r = -.07, NS.  
This data fails to suggest that cognitive functioning mediates the relationship between 
depression and quality of life with these variables.   
Hypothesis 10 
 Quality of life will improve after cardiac transplantation compared with quality of 
life with device.  To test for significant differences, a one-way analysis of variance using 
KCCQSUM scores was performed.  Results indicated that there were significant 
differences between the groups (ESHF, Device, and OHT): F (2, 11) = 8.20, p < .01.   
 A Multivatiate Analysis of Variance was also performed to use all quality of life 
subscales; KCCQ Activity, KCCQ Pain, SF-36 Activity, and SF-36 Pain.  Results 
indicated there were significant differences between the groups: F = 6.1, p < .05.  
Adjusted R Squared values (indicating variance accounted for) were as follows: .48 for 
KCCQ Activity, .28 for KCCQ Pain, .34 for SF-36 Activity, and -.13 for SF-36 Pain.   
Gender Analyses 
 Follow-up analyses compared men and women on quality of life data.  One-way 
ANOVAs did not yield significant differences between men and women.   
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CHAPTER 5 
DISCUSSION 
 
Cognitive functioning, quality of life, and emotional well-being are salient factors 
in the lives of end-stage heart failure patients receiving cardiac assist devices or 
transplants to prolong their life.  The present study provided a description and analysis of 
this fragile population: quality of life and quality of dying.  The focus was two-fold: 1) to 
compare cognitive functioning of ESHF and MCAD candidates and 2) to describe quality 
of life in relation to depressive symptoms, neuropsychological impairment, cognitive 
functioning, and status (e.g., ESHF, MCAD, or OHT).  Overall, results were consistent 
with the current literature on end-stage heart failure patients.  Results also provided new 
additional information not currently available in the literature on patients receiving 
cardiac assist devices in comparison to end-stage heart failure inpatients. 
Cognitive Functioning 
 Overall, cognitive results were not surprising.  However, there were several 
unusual findings, which warrant explanation.  As predicted, ESHF inpatients performed 
better than MCAD candidates on most cognitive measures.  Because MCAD candidates 
were “sicker” than ESHF inpatients, MCAD candidates’ cognitive functioning was 
expected to be more declined.  Results indicated that ESHF patients had better verbal 
memory, visual memory, overall memory (Memory Quotient), Logical Memory, 
cognitive processing speed, and finger tapping speed than MCAD candidates.   
 Contrary to original hypotheses, MCAD candidates performed better than ESHF 
inpatients on the Mental Status Exam, Visual Reproduction subtest of the Wechsler 
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Memory Scale, and grip strength task.  ESHF inpatients made more errors than MCAD 
candidates on the Mental Status Exam.  Although this difference may not be clinically 
significant, it is certainly curious.  The difference could be due to the measure or the 
differing mental status of the groups.  Although the MCAD candidates performed better 
than ESHF inpatients on the Visual Reproduction Immediate, they did not perform better 
on the Visual Reproduction Delay subtest.  Differences in gender or artistic ability may 
explain this finding.  Finally, MCAD candidates performed better than the ESHF 
inpatients on the grip strength task for the nondominant hand.  This may be due to the 
placement of IntraVenous lines in these patients, hindering performance or differences in 
grip strength between the groups due to gender although the MCAD group had more 
females than the ESHF group.   
Quality of Life 
 Results of the current study indicated that there is a significant positive 
relationship between depressive symptoms and neuropsychological impairment and a 
significant negative relationship between depressive symptoms and quality of life.  There 
was also a significant negative correlation between depressive symptoms and KCCQ 
Pain/Distress and a significant positive correlation between depressive symptoms and SF-
36 Pain scores.  Self-reported neurological symptoms had an inverse relationship with 
KCCQ Pain/Distress scores.  Results did not support the hypothesis that cognitive 
functioning mediates the relationship between depression and quality of life.  In addition, 
follow-up analyses indicated there were no significant gender differences for quality of 
life data.   
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 Overall, these results are consistent with the sparse current literature.  In a recent 
study of quality of life and cognitive status, Dew and colleagues (2001) found that 
patients with ventricular assist devices had poorer cognitive status and were less likely to 
return to work than non VAD patients.  However, this study did not include a complete 
neuropsychological evaluation and therefore did not determine precise levels of cognitive 
impairment.  Dew and colleagues also purport that cognitive impairment leads to 
reductions in daily functioning and quality of life.   
In an empirical evaluation of quality of life in 2 cardiac assist device recipients 
(outpatients while awaiting OHT), Dew, Simmons, Roth, Schulberg, Thompson, 
Armitage, and Griffith (1994) found that physical functional well-being, psychological 
well-being, and social functioning, was similar to other heart transplant candidates 
without devices.   
Limitations to Current Study 
 The major limitation of this study is the small sample size of cardiac assist device 
recipients.  Despite the discrepancy in sample sizes of the two groups being compared, 
equal variances within the two groups were assumed allowing for meaningful 
comparisons.  The small sample size of MCAD candidates is due to the fragility and 
mortality of the population.  When heart failure patients become candidates for cardiac 
assist devices, it is a last resort for prolonging their lives.  They are critically ill and 
unstable hemodynamically; "long-term treatment if critically ill patients is admittedly 
burdened by a high in-hospital and early follow-up mortality," (Isgro, Skuras, Kiessling, 
Lehmann, & Saggau, 2002, p. 100).  The median survival time is 30 days or less without 
transplantation with an overall life expectancy estimation of 6-9 months (Thompson & 
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Shapiro, 1994).  With transplantation, the survival rate is 80% for one year and 70% for 5 
years.  Furthermore, deconditioning, sleep and sensory deprivation contribute to their 
altered mental status and adjustment difficulties.  Even if they do survive, it is very 
difficult to get them to complete cognitive evaluations or self-report questionnaires.  The 
small amount of data collected is valuable and novel to this line of research.   
 Defining Quality of Life.  The major challenge of quality of life research with this 
population is defining quality of life.  This study operationalized quality of life with 
disease-specific and general health related quality of life measures.  The disease-specific 
measure assessed activity limitation and symptom presence related to congestive heart 
failure.  The general health related quality of life measure assessed how much health 
problems have limited activities and pain and psychological distress.   
Future Research 
 Future research should continue to assess both cognitive functioning and quality 
of life of MCAD recipients including the new and permanent devices such as the 
AbioCor Total Artificial Heart for biventricular replacement.  New left ventricular assist 
devices include the HeartMate, Novacor, Arrow LionHeart LVD-2000, and HeartSaver.  
Left ventricular replacement devices include the HeartMate, Novacor, Arrow LionHeart 
LVD-2000, and HeartSaver.  Continuous-flow left ventricular assist devices include the 
HeartSaver, Jarvik 2000, MicroMed DeBakey, and the HeartMate II.  Assessments 
should also be conducted at various time periods, although the challenge of conducting 
multiple assessments with this population is well known. 
 Recently, the Randomized Evaluation of Mechanical Assistance Therapy as an 
alternative in Congestive Heart failure (REMATCH) trial has shown a "clear benefit in 
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terms of survival and improved quality of life.  MCS should therefore no longer be 
considered as simply a temporary bridge to other therapies, but also a destination therapy 
whose potential should continue to expand through the development and use of newer, 
more innovative devices such as continuous flow pumps, next-generation centrifugal 
pumps, and total artificial hearts," (Frazier, 2002, p. 178).   
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CONCLUSIONS 
 This study has provided invaluable information about cognitive functioning and 
quality of life with MCAD candidates.  However, much remains unknown about the 
specific effects of the different devices and Inotropic support precisely on cognitive 
functioning and the subsequent impact on quality of life.  Future research should aim to 
refine the relationship between cognitive functioning and quality of life with this fragile 
population over several time periods (i.e., pre-, peri-, and post-transplant).  However, the 
reality of obtaining such data is extremely difficult.  Perhaps funding would help, but the 
expedience of collecting neuropsychological data in the intensive care unit will still 
remain a challenge. 
 In summary, the major findings of the study were: 
1) These patients are resilient in comparison to the general population; their 
cognitive functioning was actually in the normal range and they were not 
depressed.  This fits well into the health psychology literature of human 
resiliency in response to disease and adversity.  Clinical psychologists look for 
and seek to implement positive changes in people.   
2) There was a strong relationship between self-report depressive symptoms and 
self-reported neurological impairment.   
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Footnote 
1Dr. John Spertus, MD, MPH granted copy permission of use of the KCCQ for this  
 
project.   
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Table 1 
Survival Statistics for Cardiac Transplantation 
 
2,000 transplants annually 
 
Median waiting time: 226 days 
20-40% of candidates died while waiting in 1996 (Savage & Canody) 
30-40% of transplant candidates expire due to hemodynamic instability while waiting  
 
donor hearts.   
 
 
Heart transplant recipients  74% male 
 
78% white 
 
20% between the ages of 35 and 49 
 
50% were between the ages of 50 and 60 
(American Heart Association) 
 
 
1 year survival rate   80% (McGee & Horgan, 1996) 
 
     83%(NIH) 
 
     85% (Levensen & Olbrischk, 1993) 
 
85.7% (between 1996 and 1997) 
     (American Heart Association) 
        
2 year survival rate   78% (NIH) 
 
3 year survival rate   76.7%(American Heart Association) 
 
     74% (NIH) 
 
4 year survival rate   71% (NIH) 
 
5 year survival rate   72% (McGee & Horgan, 1996) 
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70-82% (Walter, Mohan, & Dahan-Mizrahl, 1992; 
Shapiro, 1992) 
 
75% (Levensen & Olbrisch, 1993) 
 
     70% to 80% (Shapiro, 1996).   
   25% suffer diffuse coronary atherosclerosis  
(Walter et al.) 
 
10 year survival rate   74% (Walter, Mohan, & Dahan-Mizrahl, 1992;  
Shapiro, 1992)  
 
Survival rates for patients on inotropes (epinephrine, dobumatmine, dopamine, &  
 
milrinone)  
     2% (no inotropes) 
 
     3% (low-dose inotropes) 
 
`    7.5% (moderate-dose) 
 
21% (one-high-dose) 
 
42% (two -high-dose) 
 
80% (three-high-dose) (Samuels et al., 1999).   
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Table 2 
Cardiac Assist Devices 
 
Bridges to Recovery  Bridges to Transplantation  Alternative to  
transplantation 
 
Intraortic Balloon Pump   Thoratec             TCI HeartMate 
Abiomed BVS 5000   TCI HeartMate I (pulsatile)          Arrow Lionheart  
TCI HeartMate II (axial)          (magnetic) 
TCI HeartMate III  
(centrifugal magnetic) 
NASA-Debakey 
Jarvik 2000 LVAD 
Arrow-Lionheart  
 
Device Support Ranges  Energy Source Pump Position    Flow Characteristics 
short-term   Pneumatic  extra-corporeal Pulsatile 
intermediate-term  Electric  para-corporeal  Centrifugal 
long-term   Alternative  Implantable   Axial 
   (nuclear or ionic) 
   Skeletal muscle power (i.e., latissimus dorsi) 
   Farrar, Riechenbach, & Hill, 1995) 
 
HeartMate (Thermo Cardisystems, Inc, Woodburn, Mass) Left Ventricular Assist Device   
long-term 
implantable 
electric device  
textured surface (facilitates the forming of biological lining, a psuedo-neointima), 
does not require anticoagulation; aspirin is sufficient   
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FDA approved HeartMate pneumatic in 1994 
Abiomed BVS 5000 (Abiomed, Inc., Danvers, Mass.) 
 short-term (days to weeks) bridge to recovery   
extracorporeal, pulsatile, pneumatic device with a smooth surface (requires 
anticoagulation) 
Automatic pulsatile pump  
pumps 4.5-6.5 L/min  
Provides univentricular or biventricular support with dual chamber design 
Supports left or right side of the heart (or both) 
Right-sided support, the device draws blood from the right atrium and 
returns blood to the pulmonary artery 
Left sided support, the device draws blood from the left atrium and returns 
blood to the aorta 
Patients are bed bound  
FDA approved as rescue-to-recovery only 
Patients with the Abiomed device reported better quality of life than medical 
management (inotropes) but less than transplant (Petrucci et al., 1999).  
 
Novacor (Novacor Division, Baxter Healthcare Corp. Oakland, CA) 
 long-term (months to years) support 
implantable, electric, and pulsatile with a smooth surface, thereby requiring 
anticoagulation (i.e., coumadin).   
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includes an implantable blood pump, electromagnetic energy converter, and an 
extracorpal computer control 
high rate of thromboembolic complications (DiBella et al., 2000)  
Device Complications With the Novacor LVAS  
 inflow valve regurgitation 
inflow canula obstruction 
outflow valve regurgitation 
outflow canula obstructon) 
cardiac tamponade (Lavee et al., 1990) 
lead to changes in perfusion pressures and filling rate and ejection rate 
(Mandarino et al., 1990).   
 
Thoratec VAD  
provides adequate circulatory support for more than 30 days despite left atrial or 
left ventricular cannulation (Holman et al., 1995).   
left atrial cannulation causes more neurologic events than left ventricular 
canulation (Holman et al.).   
Perioperative Survival Rates Are High 
efficient LVAD (decompresses the left heart effectively) 
mean pulmonary capillary wedge pressure of 1mm Hg 
low pulmonary vascular resistances 
low transpulmonary pressure gradients (Koul et al).   
Postoperative Complication Rate Are High 
fragile condition of the patients and the device itself 
Biological valve dysfunction  
post-LVAD right heart failure (19% of patients) (Koul et al.).  
Early Device Complications 
Hemorrhage at implantation 
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Right side heart failure 
Air embolism 
Multisystem organ failure 
Late Complications (greater than 30 days) 
Device failure (Goldstein, Oz, & Rose, 1998).   
Infection (Goldstein, Oz, & Rose, 1998; Griffith et al., 1996) 
Thromboembolism: 20-30% 
HeartMate has demonstrated reduced thrombolembolic events of only 4%, (Reilly 
et al., 2000) 
Abnormalities in Blood Rheology Explaining Device Complications 
increases in blood viscosity 
erythrocyte rigidity 
fibrinogen concentration 
platelet aggregation explain some device complications (Hung et al., 1989).   
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Table 3 
Demographic Information for ESHF and MCAD Candidates 
ESHF Inpatients     MCAD Candidates 
N  298       53 
Gender 245m/53f      28m/25f 
Age  49.42(17-68)      51.9(21-69) 
Education 12.55(5-22)      12.55(9-18) 
Etiology: 
Ischemic 153       23 
Idiopathic 100       25 
Structural 10       0 
Congenital 25       0 
Other  10       5 
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Table 4 
Comparing Cognitive Functioning for ESHF and MCAD Candidates 
 
   298 ESHF Mean (SD)   MCAD Mean (SD) 
MSE # errors   1.98 (2.11)     .75 (1.16) 
Benton C   6.27 (.10)     4.92 (2.05 
Benton E   5.81 (.21)     7.08 (3.40) 
Trails A (seconds)  48.2 (1.12)     68.2 (37.95) 
Trails B (seconds)  102.6 (3.58)     119.2 (69.66) 
Grip Strength (D)  33.0 (.67)     31.2 (8.19) 
Grip Strength (ND)  30.7 (.63)     31.6 (8.94) 
Finger Oscillation (D)  44.9 (.51)     41.2 (10.09) 
Finger Oscillation (ND) 40.3 (.44)     38.5 (9.13) 
Hooper   24.82 (.19)     22.92 (3.37) 
WMS MQ   103.54 (1.02)     97.85 (13.63) 
WMS LM   7.3 (.17)     6.3 (2.06) 
WMS LM-d   5.2 (.17)     4.7 (2.81) 
WMS VR   8.1 (.19)     9.4 (4.67) 
WMS VR-d   6.3 (.21)     5.7 (4.48) 
 
* p < .05, one tailed 
** p < .01, one tailed 
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Table 5 
Comparing Rey Auditory-Verbal Learning Task Performance for ESHF and MCAD 
Candidates 
 
Trial  ESHF  MCAD  t  df  p  
1  5.34  4.46   10.31  12, 139 001 
2  7.58  6.61   10.40  12, 140 001 
3  8.81  8.31   9.44  12, 140 001 
4  9.83  7.00   7.55  12, 140 001 
5  10.45  8.54   7.79  12, 140 001 
B  5.04  3.92   8.54  12, 140 001 
6  8.15  5.85   5.97  12, 140 001 
Total  42.37  37.49   20.34  34, 131 001 
 
* p < .05, one tailed 
** p < .01, one tailed 
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Table 6 
Quality of Life Scores (N=23) 
 
Measure   Range  Mean  SD  
KCCQ    30-116  78.57  27.84 
KCCQ Activity  10-53  33.13  15.62 
KCCQ Symptom  10-60  34.95  13.93 
SF-36    56-90  67.73  9.67 
SF-36 Activity  10-29  18.0  7.28 
SF-36 Pain/Distress  13-40  23.71  6.84 
BDI-II    0-37  11.79  9.00 
NIS    15-60  57.35  33.03 
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Table 7 
Correlation Matrix for Depressive Symptoms, Self-reported Neurological Impairment, 
and Quality of Life (N = 23) 
   
  BDITOT NISTOT KCCQSUM SF36SUM 
________________________________________________________ 
BDITOT   .79**  -.65*  -.01 
NISTOT     -.51  -.07 
KCCQSUM       .13 
SF36SUM 
 
* p < .05, two tailed 
** p < .01, two tailed 
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Table 8 
Correlation Matrix for Depressive Symptoms, Self-reported Neurological Impairment, 
and Quality of Life Subscales (N=23) 
 
  BDITOT    NISTOT      KCCQA KCCQP SF-36A      SF-36P 
________________________________________________________________________ 
BDITOT   .79**  -.51 -.69**  -.38  .50* 
NISTOT        -.40  -.54**  -.29  .53* 
KCCQ Activity     .81**  .54*  -.36 
KCCQ Pain        .55*  -.36 
SF-36 Activity         -.42 
SF-36 Pain 
 
* p < .05, two tailed 
** p < .01, two tailed 
 
